发明名称 COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
摘要 Methods for treating cancer include administering a therapeutically effective amount of an immunomodulatory agent such as interferon gamma 1b in combination with a therapeutically effective amount of a PD-1 checkpoint inhibitor such as nivolumab or pembrolizumab or a therapeutically effective amount of a PD-L1 checkpoint inhibitor.
申请公布号 US2017021019(A1) 申请公布日期 2017.01.26
申请号 US201615216585 申请日期 2016.07.21
申请人 Zibelman Matthew;Plimack Elizabeth;Grahn Amy;Devane John Gerard;Sherman Jeffrey W. 发明人 Zibelman Matthew;Plimack Elizabeth;Grahn Amy;Devane John Gerard;Sherman Jeffrey W.
分类号 A61K39/395;C07K16/28;A61K38/21 主分类号 A61K39/395
代理机构 代理人
主权项 1. A method for treating cancer, comprising administering to a patient in need thereof (a) a therapeutically effective amount of an immunomodulatory agent, and (b) a therapeutically effective amount of a PD-1 checkpoint inhibitor and/or a therapeutically effective amount of PD-L1 checkpoint inhibitor.
地址 Philadelphia PA US
您可能感兴趣的专利